Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28216747 | 0.86 | MEN1 (0.48) | SMN1; SMN2MEN1KMT2ANPSR1FKBP1A | |
| SCHEMBL3787663 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL31336435 | 0.85 | CYP2C19 (0.44) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL630719 | 0.84 | MEN1 (0.46) | SMN1; SMN2MEN1KMT2ANPSR1FKBP1A | |
| SCHEMBL13156117 | 0.83 | MEN1 (0.45) | SMN1; SMN2MEN1KMT2ANPSR1FKBP1A | |
| SCHEMBL17171331 | 0.83 | — | — | |
| SCHEMBL31375608 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL17157174 | 0.83 | — | — | |
| SCHEMBL13156116 | 0.83 | MEN1 (0.45) | SMN1; SMN2MEN1KMT2ANPSR1FKBP1A | |
| SCHEMBL13156114 | 0.82 | MEN1 (0.44) | MEN1KMT2ANPSR1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144630-A2 | CHK1 INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | AstraZeneca AB (SE) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008132500-A2 | CHKL INHIBITORS WITH B CELL DEPLETING ANTIBODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |